Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in Relapsed High-Grade Ovarian Cancer (ARIEL2)
NCT01891344Phase 2Completed
- Sponsor
- pharma&
- Start
- Oct 2013
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of rucaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by pharma&. Started Oct 2013; status: completed.
02
Drugs
rucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01891344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891344.